P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease

Abstract

Background Widespread use of lenalidomide (Len) as standard first-line therapy for patients (pts) with multiple myeloma (MM) has resulted in a need for Len-sparing treatments in relapsed/refractory (RR) MM. The CANDOR study (NCT03158688) demonstrated prolonged median progression-free survival (PFS) with carfilzomib, dexamethasone, and daratumumab (KdD) versus Kd alone in pts with RRMM (28.6 vs 15.2 mo; Hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.45–0.78) that was consistent across clinically relevant subgroups (Dimopoulos Blood 2020). Autologous stem cell transplantation (ASCT) is frontline standard of care for MM, particularly for younger pts without severe comorbidities. Thera..